Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs L3Harris Technologies Inc (LHX) Price & Performance

Davita IncTrade
L3Harris Technologies IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs L3Harris Technologies Inc — how do they compare? Davita Inc trades at $181.62 (market cap $11.38B), while L3Harris Technologies Inc trades at $289.93 (market cap $53.26B). The key difference: L3Harris Technologies Inc is far larger — about 4.7× Davita Inc's market cap, and L3Harris Technologies Inc pays a 1.75% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

DVALHX
Market Cap
$11.38B$53.26B
Sector
HealthIndustrials
52-Week High
$240.96$378.48
52-Week Low
$103.87$270.21
Enterprise Value
$24.10B$63.71B
Dividend Yield
1.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $180.25, down 1.87% amid mixed signals. The stock shows strong earnings momentum with three consecutive quarterly beats (Q4 2025-Q2 2026) but faces margin pressure. Technical indicators are conflicted with a bullish overall signal but bearish moving averages. Revenue growth remains steady, climbing from $11.6B in 2022 to $13.6B in 2025, though net income margin fluctuated between 4.82% and 7.3% over the same period.

The outlook is cautiously optimistic with a $232.25 consensus price target offering 29% upside. Key risks include reimbursement pressure and high debt levels (debt-to-asset ratio of 65.55% in 2025). Analyst sentiment leans neutral (56.52% Hold) despite recent earnings strength, reflecting concerns about payer mix and margin sustainability.

L3Harris Technologies Inc

LHX trades at $285.18, down 1.57% today, with strong fundamental performance including three consecutive quarterly EPS beats and record $42 billion backlog. The company shows improving profitability with net margin expanding to 8.11% in 2026 projections. Recent defense contract wins and successful missile tests highlight operational momentum, though technical indicators show bearish pressure with price below key resistance levels.

LHX presents a compelling investment case with strong defense sector positioning, consistent earnings outperformance, and 72.7% analyst buy ratings targeting $319.33. Key risks include defense budget volatility and execution challenges in scaling production. The stock offers 12% upside to consensus target with dividend yield support, though near-term technical weakness requires monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About L3Harris Technologies Inc

L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.

Read more on LHX